Evidence-Based Neurology
CATEGORY: Cognitive / Behavioural Disorders

Donepezil did not improve cognitive impairment or prevent the progression to Alzheimer's disease in individuals with Mild Cognitive Impairment
Date appraised: July 2007
[HTML] [PDF]

In suspected sporadic CJD, the diagnostic sensitivity and specificity of MRI was 67% and 93% respectively
Date appraised: May 2005
[HTML] [PDF]

Age, anemia, opportunistic infection, and low CD4 counts increased the risk of HIV dementia
Date appraised: April 2005
[HTML] [PDF]

CSF hypocretin-1 levels may be useful as a confirmatory test for clinically suspected narcolepsy
Date appraised: September 2004
[HTML] [PDF]

The evidence did not support the use of HMG-CoA Reductase Inhibitors to prevent dementia
Date appraised: June 2003
[HTML] [PDF]

Five heterogeneous studies suggested that patients with MCI or similar conditions had an increased risk of progression to Alzheimer's disease, ranging between 6% and 25% per year.
Date appraised: December 2002
[HTML] [PDF]

Cerebrospinal fluid 14–3–3 protein testing was highly sensitive and specific for patients with a clinical suspicion of Creutzfeldt-Jakob disease
Date appraised: June 2002
[HTML] [PDF]

Rivastigmine (6-12 mg daily) produced clinical and behavioral improvement in patients with Lewy-body dementia and was relatively well tolerated.
Date appraised: March 2002
[HTML] [PDF]

Depressed elderly outpatients and inpatients improve on depression scale scores with TCA's (NNT 4), and SSRI's (NNT 8).
Date appraised: February 2002
[HTML] [PDF]

Modafinil was safe and reduces excessive daytime sleepiness in narcoleptic patients, although the benefits are small.
Date appraised: April 2000
[HTML] [PDF]

In clinically suspected CJD, an EEG with periodic sharp waves significantly increases the probability of CJD. Their absence do not rule out CJD.
Date appraised: December 1999
[HTML] [PDF]

Donepezil (Aricept) slowed the progression of Alzheimer's disease up to one year, but the clinical significance is questionable
Date appraised: August 1998
[HTML] [PDF]

Extract of Gingko Biloba (EGb 761) may slow progression of dementia.
Date appraised: July 1998
[HTML] [PDF]